Achieving culturаl аnd linguistic cоmpetence cаn require a dramatic shift in persоnal and оrganizational culturalbeliefs, values, policies, and practices.
Initiаl Pоst оn Obesity Intrоduction One of the significаnt аnd rising health problems in the United States is obesity. Obesity is defined as an excess consumption of calories compared to calories expended by an individual, resulting in excess body fat (Capriotti, 2024). Clinically, obesity is measured using a height to weight ratio called body mass index (BMI), with a BMI greater than or equal to 30 being classified as obese (Capriotti, 2024). Those who lack physical activity are at a higher risk of obesity, along with the disorders that come with it. These disorders can include cardiovascular disease, diabetes mellitus, gallbladder disease, sleep apnea, poor wound healing, as well as various forms of cancer (Capriotti, 2024). Although obesity is associated with excess weight gain, it is a disease also connected with metabolic dysfunction, inflammation, and poor energy regulation (Menendez et al., 2022). People differ in how they gain weight even when caloric intake and activity is identical. This suggests that obesity is a chronic disease and not just a result of a poor lifestyle, and this is crucial information to consider when discussing prevention and treatment of obesity (Menendez et al., 2022). This paper will analyze obesity as a chronic disease by highlighting its causes, metabolic dysfunctions, and its evolving pharmacological treatment. Physical Inactivity and Risk Factors The development of obesity can be influenced by multiple factors such as genetics, socioeconomic, environment, and race (Capriotti, 2024). The risk of cardiovascular disease and the level of physical activity go hand in hand. Those who exercise on a regular basis demonstrate a lower risk of coronary artery disease and fewer acute cardiac events (Capriotti, 2024). Exercise also stimulates vascular endothelial growth factor secretion, which induces synthesis of new blood vessels by endothelial cells (Capriotti, 2024). If the body is unable to expend the energy it takes in, then it becomes stored as fat. The lack of physical activity has become a public problem in the United States (Capriotti, 2024). Whether individuals are paralyzed, undergoing rehabilitation, healing, or choosing to be inactive, they are at a risk of immobilization. Regardless of the cause, immobility is a risk factor for obesity, cardiovascular issues, muscle atrophy, and other diseases (Capriotti, 2024). Pathophysiology of Obesity Changes in cellular insulin activity, glucose use, fat accumulation, and lipid balance cause the metabolic disorder of obesity (Capriotti, 2024). Fat cells called adipocytes secrete hormones and proteins called adipokines, which affect body metabolism (Menendez et al., 2022). The three main functions of adipocytes are lipid storage, secretory function, and insulin sensitivity (Menendez et al., 2022). In obesity, adipocytes increase in size and number, contributing to cellular dysfunction (Capriotti, 2024). Adipocytes also make up the majority of adipose tissue, which provides insulation, warmth, and cushioning for the body’s organs (Menendez et al., 2022). The more adipose tissue in the body, the greater the number of adipokines which influence hunger and appetite (Menendez et al., 2022). Adipose Tissue and Inflammation During homeostasis, adipose tissue helps regulate energy as it stores excess energy in the form of triglycerides and releases fatty acids when energy is demanded (Menendez et al., 2022). However, in obesity, adipose tissue becomes chronically inflamed (Capriotti, 2024). This inflammation causes excess fat to build up in adipose tissue, as well as liver and skeletal muscle (Capriotti, 2024). Limited oxygen supply occurs in adipose tissue as it expands beyond its typical capacity, adipocytes get larger, and hypoxic conditions occur (Menendez et al., 2022). The hypoxia releases harmful molecules such as endocrine hormones, cytokines, exosomes, miRNA, lipids, and peptide hormones (Menendez et al., 2022). These molecules alter proper metabolic balance, immune regulation, and physiological stability, showing that adipose tissue influences many metabolic processes in the body. (Menendez et al., 2022). Management of Obesity with Medication Effective obesity management requires a personalized and disciplined approach that combines lifestyle changes with medications when appropriate. Evidence shows that pharmacological treatment has become an important factor of obesity management, especially for those who struggle to achieve long-term success through lifestyle changes (Ostrominski et al., 2025). Medications for obesity treatment are recommended for individuals with a BMI of 30 or greater, or 27 or greater when other complications are present (Ostrominski et al., 2025). These medications do not just help reduce caloric intake, but they are used to support weight loss by confronting abnormal appetite, metabolic dysfunction, and glycemic control (Ostrominski et al., 2025). Limitations of Obesity Medications There has been recent research done to express the effectiveness of obesity medications, specifically glucagon-like peptide 1 receptors (GLP-1), which is also used to treat type 2 diabetes (Capriotti, 2024). Ostrominski conducted a survey where 91% of participants reported using GLP-1 agonists such as semaglutide, tirzepatide, or liraglutide. The majority of these participants reported having a positive experience with these medications including reductions in body weight and appetite (Ostrominski et al., 2025). Those who stayed on the medication for six months or longer experienced better outcomes compared to those who took the medication for a shorter duration (Ostrominski et al., 2025). Pharmacological treatment can play a crucial role in improving metabolic health related to obesity. However, Capriotti reports that long-term maintenance of these improvements remains uncertain (Capriotti, 2024). Despite the reported benefits of obesity medication, there are several factors that limit its effectiveness. Ostromski stated that there are obstacles for the pharmacological treatment of obesity such as insurance restrictions, high medication cost, and concerns about side effects (Ostrominski et al., 2025). Many participants only stay on medication for a short period of time due to financial reasons and the majority reported unclear communication with the provider (Ostrominski et al., 2025). Even with legitimate results of medication for obesity management, it is unknown if long-term success can be guaranteed (Ostrominski et al., 2025). Conclusion In summary, obesity is a complex chronic disease influenced by lack of metabolic function, adipose tissue inflammation, physical inactivity, environmental factors, and socioeconomic factors (Capriotti, 2024; Menendez et al., 2022). When adipose tissue function is disrupted, insulin resistance, inflammation, and potential long-term health issues can be developed (Menendez et al., 2022). While lifestyle changes such as diet and physical activity are essential factors in obesity management, they are not fully effective on their own (Ostrominski et al., 2025). Pharmacological treatments, specifically GLP-1 receptor agonists, can be used to help with weight reduction and improve metabolic functions in individuals dealing with obesity (Capriotti, 2024; Ostrominski, et al., 2025). However, it needs to be noted that restrictions such as cost, communication, and access may limit the medications effectiveness (Ostrominski et al., 2025). The best form of obesity management is an individualized approach using lifestyle modifications and medical assistance, as well as clear communication. References Capriotti, T. (2024). Davis Advantage for Pathophysiology. F.A. Davis. Menendez, A., Wanczyk, H., Walker, J. Ahou, B., Santos, M., & Fink, C. (2022). Obesity and Adipose Tissue Dysfunction: From Pediatrics to Adults. Genes, 13(10) https://link.gale.com/apps/doc/A745723260/HRCA?u=tel_a_freehu&sid=bookmark-HRCA&xid=c0bae5d6Links to an external site. Ostrominski, J. Chibber, A., Kuti, E. L., Clark, B., & Donato, B.M. (2025). Obesity Medication Treatment Perspectives Among People with Overweight or Obesity. Patient Preference and Adherence, 19, 2887. https://link.gale.com/apps/doc/A860653472/HRCA?u=tel_a_freehu&sid=bookmark-HRCA&xid=fc6b0f72
The vаlue оf а firm depends оn аll оf the following EXCEPT: